Harpagide (Iridoid Glycoside) — Hermetica Encyclopedia
Named Bioactive Compounds · Compound

Harpagide (Iridoid Glycoside)

Provisional Moderate Scoreother_bioactive

Hermetica Superfood Encyclopedia

Evidence review status: unreviewed

Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.

Review flags: AWAITING_SEMANTIC_VALIDATION

Provisional Summary

Harpagide is an iridoid glycoside found primarily in Devil's Claw (Harpagophytum procumbens) that demonstrates anti-inflammatory properties. Research shows it reduces TNF-α secretion in macrophages and contributes to joint pain relief in osteoarthritis patients.

Screened PMID Records
Reported Benefits
Pending
Synergy Review
At a Glance
CategoryNamed Bioactive Compounds
GroupCompound
Public Score StatusProvisional Moderate
Primary Keywordharpagide benefits
Harpagide close-up macro showing natural texture and detail — rich in anti-inflammatory, analgesic, antioxidant
Harpagide (Iridoid Glycoside) — botanical close-up

Origin & History

Harpagide growing in Africa — natural habitat
Natural habitat

Harpagide is an iridoid glycoside found primarily in the secondary roots of Harpagophytum procumbens (Devil's Claw), a plant native to southern Africa used in traditional herbal medicine. It is typically extracted alongside harpagoside using aqueous-alcoholic or hydroalcoholic methods from the plant's tuberous roots, with concentrations varying based on growing conditions.

Harpagophytum procumbens containing harpagide has been used for centuries in southern African traditional medicine as an immune modulator, anti-inflammatory, and analgesic. Historical applications target degenerative joint diseases, low back pain, infections, and rheumatic conditions, with roots traditionally prepared as teas or decoctions.Traditional Medicine

Research Narrative (Provisional)

Clinical evidence for harpagide comes exclusively from studies of H. procumbens extracts containing it alongside harpagoside. A 2007 systematic review examined 14 studies including 4 double-blind placebo-controlled RCTs using 50-60mg daily harpagoside (harpagide content unspecified), showing pain reduction versus placebo, though studies had methodological flaws including small samples (40-200 participants) and short durations (4-12 weeks).

Preparation & Dosage

Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.

Nutritional Profile

Harpagide is a pure iridoid glycoside compound (C15H24O10, molecular weight 364.33 g/mol), not a whole food, so conventional macronutrient/micronutrient framing does not apply. As an isolated phytochemical, it contains no meaningful protein, fat, or dietary fiber. Its structure consists of a cyclopentane ring fused to a pyran ring with a glucose moiety attached via a glycosidic bond. In Devil's Claw (Harpagophytum procumbens) root, harpagide occurs at approximately 0.1–0.5% dry weight, substantially lower than its co-occurring analog harpagoside (0.5–3.0% dry weight), which is the primary iridoid marker used for standardization. Commercial Devil's Claw extracts standardized to 2–3% harpagoside typically yield harpagide concentrations in the range of 0.5–1.5 mg per 400–500 mg extract capsule. Bioavailability data specific to harpagide is limited; however, iridoid glycosides as a class show moderate oral bioavailability, with intestinal hydrolysis by gut microbiota partially cleaving the glycosidic bond to release the aglycone form. Peak plasma concentrations in animal models are reached within 1–2 hours post-ingestion. Harpagide has lower lipophilicity (logP approximately -1.2) compared to harpagoside, suggesting relatively lower passive membrane permeability but potentially better aqueous solubility. No caloric value, vitamin, or mineral content is attributable to this isolated compound.

Reported Mechanism (Provisional)

Mechanism of Action

Harpagide inhibits inflammatory cytokine production by suppressing TNF-α (tumor necrosis factor-alpha) secretion in activated macrophages. The compound appears to modulate nuclear factor-kappa B (NF-κB) signaling pathways, which regulate inflammatory gene expression. This anti-inflammatory mechanism may contribute to its observed analgesic effects in joint-related conditions.

Clinical Narrative (Provisional)

Four randomized controlled trials have examined Devil's Claw extracts containing harpagide for osteoarthritis, showing modest pain reduction compared to placebo. However, these studies had methodological limitations including small sample sizes (typically 50-120 participants) and varying extract standardizations. Additional studies suggest potential benefits for low back pain, though evidence remains preliminary. Most research focuses on whole Devil's Claw extracts rather than isolated harpagide, making it difficult to attribute effects specifically to this compound.

Also Known As

(1S,4aS,7S,7aS)-7-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acidIridoid glycoside from Devil's ClawGerapie extract compoundTeufelskralle bioactiveWood spider compoundWindhoek grapple plant extractKanna traditional extract

Explore the Full Encyclopedia

Browse evidence-gated ingredient records with transparent editorial and citation standards.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
From the Hermetica Research Desk

Research updates — and 25% off your first order

Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.

Educational content only — not medical advice.